These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21868521)

  • 21. The zinc-finger transcription factor, early growth response 3, mediates VEGF-induced angiogenesis.
    Liu D; Evans I; Britton G; Zachary I
    Oncogene; 2008 May; 27(21):2989-98. PubMed ID: 18059339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Substrate-specific conformational regulation of the receptor tyrosine kinase VEGFR2 catalytic domain.
    Solowiej J; Chen JH; Zou HY; Grant SK; Murray BW
    ACS Chem Biol; 2013 May; 8(5):978-86. PubMed ID: 23441851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment.
    Akiyama K; Ohga N; Hida Y; Kawamoto T; Sadamoto Y; Ishikawa S; Maishi N; Akino T; Kondoh M; Matsuda A; Inoue N; Shindoh M; Hida K
    Am J Pathol; 2012 Mar; 180(3):1283-1293. PubMed ID: 22245726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase.
    Rizvi SU; Siddiqui HL; Nisar M; Khan N; Khan I
    Bioorg Med Chem Lett; 2012 Jan; 22(2):942-4. PubMed ID: 22200597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accumulation of VEGFR2 in zoledronic acid-treated endothelial cells.
    Basi DL; Lee SW; Helfman S; Mariash A; Lunos SA
    Mol Med Rep; 2010; 3(3):399-403. PubMed ID: 21472253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular.
    Buchanan CM; Shih JH; Astin JW; Rewcastle GW; Flanagan JU; Crosier PS; Shepherd PR
    Clin Sci (Lond); 2012 May; 122(10):449-57. PubMed ID: 22142330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A combinatorial in silico and cellular approach to identify a new class of compounds that target VEGFR2 receptor tyrosine kinase activity and angiogenesis.
    Kankanala J; Latham AM; Johnson AP; Homer-Vanniasinkam S; Fishwick CW; Ponnambalam S
    Br J Pharmacol; 2012 May; 166(2):737-48. PubMed ID: 22141913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
    Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
    J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2.
    Iwata H; Imamura S; Hori A; Hixon MS; Kimura H; Miki H
    Bioorg Med Chem; 2011 Sep; 19(18):5342-51. PubMed ID: 21885287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy.
    Ichikawa K; Watanabe Miyano S; Minoshima Y; Matsui J; Funahashi Y
    Sci Rep; 2020 Feb; 10(1):2939. PubMed ID: 32076044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VEGFR2 inhibition hampers breast cancer cell proliferation
    Ni H; Guo M; Zhang X; Jiang L; Tan S; Yuan J; Cui H; Min Y; Zhang J; Schlisio S; Ma C; Liao W; Nister M; Chen C; Li S; Li N
    Cancer Biol Med; 2021 Feb; 18(1):139-154. PubMed ID: 33628590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microtubule-targeted drugs inhibit VEGF receptor-2 expression by both transcriptional and post-transcriptional mechanisms.
    Meissner M; Pinter A; Michailidou D; Hrgovic I; Kaprolat N; Stein M; Holtmeier W; Kaufmann R; Gille J
    J Invest Dermatol; 2008 Aug; 128(8):2084-91. PubMed ID: 18323785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural investigation of the VEGF receptor interaction with a helical antagonist peptide.
    Diana D; Di Stasi R; De Rosa L; Isernia C; D'Andrea LD; Fattorusso R
    J Pept Sci; 2013 Apr; 19(4):214-9. PubMed ID: 23420665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversible acetylation regulates vascular endothelial growth factor receptor-2 activity.
    Zecchin A; Pattarini L; Gutierrez MI; Mano M; Mai A; Valente S; Myers MP; Pantano S; Giacca M
    J Mol Cell Biol; 2014 Apr; 6(2):116-27. PubMed ID: 24620033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, biological evaluation, and molecular modeling study of 4-alkoxyquinazoline derivatives as potential VEGFR2 kinase inhibitors.
    Sun J; Li DD; Li JR; Fang F; Du QR; Qian Y; Zhu HL
    Org Biomol Chem; 2013 Nov; 11(44):7676-86. PubMed ID: 24108070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis of piperazine-based thiazolidinones as VEGFR2 tyrosine kinase inhibitors inducing apoptosis.
    El-Miligy MM; Abd El Razik HA; Abu-Serie MM
    Future Med Chem; 2017 Oct; 9(15):1709-1729. PubMed ID: 28925739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combining Multikinase Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor and Cluster of Differentiation 47 Signaling Pathways Is Predicted to Increase the Efficacy of Antiangiogenic Combination Therapies.
    Zhang Y; Popel AS; Bazzazi H
    ACS Pharmacol Transl Sci; 2023 May; 6(5):710-726. PubMed ID: 37200806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiplexing Angiogenic Receptor Quantification via Quantum Dots.
    Chen S; Imoukhuede PI
    Anal Chem; 2019 Jun; 91(12):7603-7612. PubMed ID: 31088078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis.
    Makita N; Iiri T
    Thyroid; 2013 Feb; 23(2):151-9. PubMed ID: 23398161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors--review of assay methodologies and perspectives.
    Sharma K; Suresh PS; Mullangi R; Srinivas NR
    Biomed Chromatogr; 2015 Jun; 29(6):803-34. PubMed ID: 25424874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.